Gene: CSGALNACT1

55790
CSGalNAcT-1|ChGn|ChGn-1|beta4GalNAcT
chondroitin sulfate N-acetylgalactosaminyltransferase 1
protein-coding
8p21.3
Ensembl:ENSG00000147408 MIM:616615 Vega:OTTHUMG00000130827 UniprotKB:Q8TDX6
NC_000008.11
PubMed|SNP Mapped
2   ANCO-SNPs
OD|ND|AD
1   
2.634e-1 (AD)  6.503e-1 (ND)   (Frontal_Cortex)
3.673e-1 (AD)  5.602e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6983139chr8:19742818 (GRCh38.p7)A>Galcohol dependenceSNV(Single Nucleotide Variation)
rs11779629chr8:19654461 (GRCh38.p7)A>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg12741231chr8:19321936CSGALNACT1Gene body8.293e-5Alcohol use disorders26763658
cg19895047chr8:19460197CSGALNACT1Promoter2.133e-4Alcohol use disorders26763658

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
YIPF60.787
MTMR30.786
TMEM1920.777
KDM3B0.776
SNRNP2000.772
NCOA10.77
USP240.769
SLC39A90.768
COX150.764
ASPH0.763

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.584
OR4F29-0.541
STAC-0.243
ANXA13-0.225
TNFRSF13B-0.214
CHP2-0.203
IAPP-0.194
SH2D1A-0.193
ISL1-0.191
SLITRK6-0.182

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0369902-amino-3,8-dimethylimidazo(4,5-f)quinoxaline"2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline results in decreased expression of CSGALNACT1 mRNA"20816883
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of CSGALNACT1 mRNA21632981
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of CSGALNACT1 gene27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of CSGALNACT1 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of CSGALNACT1 mRNA20458559
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CSGALNACT1 mRNA22316170
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA21569818
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CSGALNACT1 mRNA22228805|2261060
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of CSGALNACT1 mRNA21839799
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide affects the expression of CSGALNACT1 mRNA"20382639
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of CSGALNACT1 mRNA"19150397
D004958EstradiolEGF protein inhibits the reaction [Estradiol results in decreased expression of CSGALNACT1 mRNA]24758408
D004958EstradiolEstradiol results in decreased expression of CSGALNACT1 mRNA24758408
C006780bisphenol Abisphenol A results in decreased expression of CSGALNACT1 mRNA27685785
C006780bisphenol Abisphenol A results in decreased expression of CSGALNACT1 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of CSGALNACT1 gene28505145
C018475butyraldehydebutyraldehyde results in decreased expression of CSGALNACT1 mRNA26079696
D002220CarbamazepineCarbamazepine affects the expression of CSGALNACT1 mRNA25979313
D002330CarmustineCSGALNACT1 mRNA affects the susceptibility to Carmustine16365179
C018021cobaltous chloridecobaltous chloride results in decreased expression of CSGALNACT1 mRNA19376846
D019327Copper SulfateCopper Sulfate results in decreased expression of CSGALNACT1 mRNA19549813
D016572CyclosporineCyclosporine results in decreased expression of CSGALNACT1 mRNA27989131
C089595cylindrospermopsincylindrospermopsin results in increased expression of CSGALNACT1 mRNA24921660
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of CSGALNACT1 mRNA27392435
D004041Dietary FatsDietary Fats results in increased expression of CSGALNACT1 mRNA28031460
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of CSGALNACT1 mRNA17005392
D002117CalcitriolCalcitriol results in increased expression of CSGALNACT1 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of CSGALNACT1 mRNA21592394
D004237DiuronDiuron results in decreased expression of CSGALNACT1 mRNA25152437
D005047EtoposideCSGALNACT1 protein affects the susceptibility to Etoposide16217747
D017313FenretinideFenretinide results in increased expression of CSGALNACT1 mRNA28973697
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of CSGALNACT1 mRNA20044591
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of CSGALNACT1 mRNA27392435
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of CSGALNACT1 mRNA23086925
D007854LeadLead affects the expression of CSGALNACT1 mRNA28903495
D058185Magnetite Nanoparticles[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of CSGALNACT1 mRNA26378955
C523799MRK 003CSGALNACT1 results in increased susceptibility to MRK 00319903844
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of CSGALNACT1 mRNA25729387
D010100OxygenOxygen deficiency results in increased expression of CSGALNACT1 mRNA26516004
D052638Particulate MatterParticulate Matter results in decreased expression of CSGALNACT1 mRNA22178795
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of CSGALNACT1 mRNA26272509
D010936Plant ExtractsPlant Extracts results in increased expression of CSGALNACT1 mRNA23557933
D011794QuercetinQuercetin results in increased expression of CSGALNACT1 mRNA21632981
C502851quinocetonequinocetone results in increased expression of CSGALNACT1 mRNA27046791
D012822Silicon DioxideSilicon Dioxide analog results in increased expression of CSGALNACT1 mRNA23806026
D012999SomanSoman results in decreased expression of CSGALNACT1 mRNA19281266
D004113Succimer[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of CSGALNACT1 mRNA26378955
C047246temozolomideCSGALNACT1 mRNA affects the susceptibility to temozolomide16365179
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of CSGALNACT1 mRNA21592394
D013739TestosteroneTestosterone results in increased expression of CSGALNACT1 mRNA21592394
C020806tetrabromobisphenol Atetrabromobisphenol A results in decreased expression of CSGALNACT1 mRNA28300664
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of CSGALNACT1 mRNA25729387
D014212TretinoinTretinoin results in increased expression of CSGALNACT1 mRNA21934132
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of CSGALNACT1 mRNA19042947
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in increased expression of CSGALNACT1 mRNA"26179874
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSGALNACT1 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased methylation of CSGALNACT1 gene29154799
D014635Valproic AcidValproic Acid results in increased expression of CSGALNACT1 mRNA23179753|2438349
D001335Vehicle EmissionsVehicle Emissions affects the methylation of CSGALNACT1 gene25560391
D015215Zidovudine[Zidovudine co-treated with IFNA1 protein] results in increased expression of CSGALNACT1 mRNA20370541

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0008376acetylgalactosaminyltransferase activity-IDA11514575  
GO:0008376acetylgalactosaminyltransferase activity-ISS11788602  
GO:0008955peptidoglycan glycosyltransferase activity-IDA11514575  
GO:0015020glucuronosyltransferase activity-IDA11514575  
GO:0046872metal ion binding-NAS12163485  
GO:0047237glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase activity-IDA12163485  
GO:0047238glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity-IDA12163485  
GO:0047238glucuronosyl-N-acetylgalactosaminyl-proteoglycan 4-beta-N-acetylgalactosaminyltransferase activity-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001958endochondral ossification-IEA-  
GO:0007399nervous system development-NAS11514575  
GO:0008037cell recognition-NAS11514575  
GO:0008283cell proliferation-NAS11514575  
GO:0009653anatomical structure morphogenesis-NAS11514575  
GO:0015014heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process-NAS11514575  
GO:0019276UDP-N-acetylgalactosamine metabolic process-IDA11514575  
GO:0030166proteoglycan biosynthetic process-ISS11788602  
GO:0030198extracellular matrix organization-NAS11514575  
GO:0030206chondroitin sulfate biosynthetic process-IDA11514575  12163485  
GO:0030206chondroitin sulfate biosynthetic process-TAS-  
GO:0030210heparin biosynthetic process-NAS11514575  
GO:0046398UDP-glucuronate metabolic process-IDA11514575  
GO:0050650chondroitin sulfate proteoglycan biosynthetic process-ISS11788602  
GO:0050651dermatan sulfate proteoglycan biosynthetic process-ISS11788602  
GO:0050653chondroitin sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process-IDA12163485  
GO:0051216cartilage development-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-TAS-  
GO:0005622intracellular-IC12163485  
GO:0030173integral component of Golgi membrane-NAS11514575  
GO:0032580Golgi cisterna membrane-IEA-  
KEGG ID KEGG Term
hsa00532Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1630316Glycosaminoglycan metabolismTAS
R-HSA-1793185Chondroitin sulfate/dermatan sulfate metabolismTAS
R-HSA-2022870Chondroitin sulfate biosynthesisTAS
R-HSA-71387Metabolism of carbohydratesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
25555482Genome-wide association study of nicotine dependence in American populations: identification of novel risk loci in both African-Americans and European-Americans. (2015 Mar 1)Gelernter JBiol Psychiatry